BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 35579942)

  • 1. A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice.
    Stavrou M; Kagiava A; Choudury SG; Jennings MJ; Wallace LM; Fowler AM; Heslegrave A; Richter J; Tryfonos C; Christodoulou C; Zetterberg H; Horvath R; Harper SQ; Kleopa KA
    J Clin Invest; 2022 Jul; 132(13):. PubMed ID: 35579942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice.
    Lee JS; Lee JY; Song DW; Bae HS; Doo HM; Yu HS; Lee KJ; Kim HK; Hwang H; Kwak G; Kim D; Kim S; Hong YB; Lee JM; Choi BO
    Nucleic Acids Res; 2020 Jan; 48(1):130-140. PubMed ID: 31713617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schwann cell differentiation in Charcot-Marie-Tooth disease type 1A (CMT1A): normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs.
    Hanemann CO; Gabreëls-Festen AA; Stoll G; Müller HW
    Acta Neuropathol; 1997 Oct; 94(4):310-5. PubMed ID: 9341930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral myelin protein-22 expression in Charcot-Marie-Tooth disease type 1a sural nerve biopsies.
    Hanemann CO; Stoll G; D'Urso D; Fricke W; Martin JJ; Van Broeckhoven C; Mancardi GL; Bartke I; Müller HW
    J Neurosci Res; 1994 Apr; 37(5):654-9. PubMed ID: 8028042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PMP22 expression in dermal nerve myelin from patients with CMT1A.
    Katona I; Wu X; Feely SM; Sottile S; Siskind CE; Miller LJ; Shy ME; Li J
    Brain; 2009 Jul; 132(Pt 7):1734-40. PubMed ID: 19447823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The alpha-chemokine CXCL14 is up-regulated in the sciatic nerve of a mouse model of Charcot-Marie-Tooth disease type 1A and alters myelin gene expression in cultured Schwann cells.
    Barbaria EM; Kohl B; Buhren BA; Hasenpusch-Theil K; Kruse F; Küry P; Martini R; Müller HW
    Neurobiol Dis; 2009 Mar; 33(3):448-58. PubMed ID: 19111616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electroceutical approach ameliorates intracellular PMP22 aggregation and promotes pro-myelinating pathways in a CMT1A in vitro model.
    Intisar A; Woo H; Kang HG; Kim WH; Shin HY; Kim MY; Kim YS; Mo YJ; Lee YI; Kim MS
    Biosens Bioelectron; 2023 Mar; 224():115055. PubMed ID: 36630746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
    Chumakov I; Milet A; Cholet N; Primas G; Boucard A; Pereira Y; Graudens E; Mandel J; Laffaire J; Foucquier J; Glibert F; Bertrand V; Nave KA; Sereda MW; Vial E; Guedj M; Hajj R; Nabirotchkin S; Cohen D
    Orphanet J Rare Dis; 2014 Dec; 9():201. PubMed ID: 25491744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Charcot-Marie-Tooth disease and related inherited neuropathies.
    Murakami T; Garcia CA; Reiter LT; Lupski JR
    Medicine (Baltimore); 1996 Sep; 75(5):233-50. PubMed ID: 8862346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schwann cell transcript biomarkers for hereditary neuropathy skin biopsies.
    Svaren J; Moran JJ; Wu X; Zuccarino R; Bacon C; Bai Y; Ramesh R; Gutmann L; Anderson DM; Pavelec D; Shy ME
    Ann Neurol; 2019 Jun; 85(6):887-898. PubMed ID: 30945774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with IFB-088 Improves Neuropathy in CMT1A and CMT1B Mice.
    Bai Y; Treins C; Volpi VG; Scapin C; Ferri C; Mastrangelo R; Touvier T; Florio F; Bianchi F; Del Carro U; Baas FF; Wang D; Miniou P; Guedat P; Shy ME; D'Antonio M
    Mol Neurobiol; 2022 Jul; 59(7):4159-4178. PubMed ID: 35501630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AAV2/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A.
    Gautier B; Hajjar H; Soares S; Berthelot J; Deck M; Abbou S; Campbell G; Ceprian M; Gonzalez S; Fovet CM; Schütza V; Jouvenel A; Rivat C; Zerah M; François V; Le Guiner C; Aubourg P; Fledrich R; Tricaud N
    Nat Commun; 2021 Apr; 12(1):2356. PubMed ID: 33883545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of PMP22 ameliorates myelin defects in iPSC-derived human organoid cultures of CMT1A.
    Van Lent J; Vendredy L; Adriaenssens E; Da Silva Authier T; Asselbergh B; Kaji M; Weckhuysen S; Van Den Bosch L; Baets J; Timmerman V
    Brain; 2023 Jul; 146(7):2885-2896. PubMed ID: 36511878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).
    Prukop T; Stenzel J; Wernick S; Kungl T; Mroczek M; Adam J; Ewers D; Nabirotchkin S; Nave KA; Hajj R; Cohen D; Sereda MW
    PLoS One; 2019; 14(1):e0209752. PubMed ID: 30650121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An essential role of MAG in mediating axon-myelin attachment in Charcot-Marie-Tooth 1A disease.
    Kinter J; Lazzati T; Schmid D; Zeis T; Erne B; Lützelschwab R; Steck AJ; Pareyson D; Peles E; Schaeren-Wiemers N
    Neurobiol Dis; 2013 Jan; 49():221-31. PubMed ID: 22940629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A.
    Perea J; Robertson A; Tolmachova T; Muddle J; King RH; Ponsford S; Thomas PK; Huxley C
    Hum Mol Genet; 2001 May; 10(10):1007-18. PubMed ID: 11331611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical characterization of protein quality control mechanisms during disease progression in the C22 mouse model of CMT1A.
    Chittoor VG; Sooyeon L; Rangaraju S; Nicks JR; Schmidt JT; Madorsky I; Narvaez DC; Notterpek L
    ASN Neuro; 2013 Dec; 5(5):e00128. PubMed ID: 24175617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AAV-mediated editing of PMP22 rescues Charcot-Marie-Tooth disease type 1A features in patient-derived iPS Schwann cells.
    Yoshioka Y; Taniguchi JB; Homma H; Tamura T; Fujita K; Inotsume M; Tagawa K; Misawa K; Matsumoto N; Nakagawa M; Inoue H; Tanaka H; Okazawa H
    Commun Med (Lond); 2023 Nov; 3(1):170. PubMed ID: 38017287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pmp22 super-enhancer deletion causes tomacula formation and conduction block in peripheral nerves.
    Pantera H; Hu B; Moiseev D; Dunham C; Rashid J; Moran JJ; Krentz K; Rubinstein CD; Won S; Li J; Svaren J
    Hum Mol Genet; 2020 Jun; 29(10):1689-1699. PubMed ID: 32356557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models.
    Zhao HT; Damle S; Ikeda-Lee K; Kuntz S; Li J; Mohan A; Kim A; Hung G; Scheideler MA; Scherer SS; Svaren J; Swayze EE; Kordasiewicz HB
    J Clin Invest; 2018 Jan; 128(1):359-368. PubMed ID: 29202483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.